{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:17:08Z","timestamp":1783019828957,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>Chronic Persistent Diabetic Macular Edema can be a clinical challenge. The aim of this study is to assess the outcomes of intravitreal brolucizumab 6\u00a0mg\/0.05\u00a0ml for persistent diabetic macular edema (P-DME) in a real-world clinical setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A prospective interventional trial of consecutive patients with P-DME was conducted at a tertiary care center in India. P-DME was defined as edema persisting despite more than three intravitreal anti-VEGF injections or despite a combination of anti-VEGFs, intravitreal steroids and\/or laser photocoagulation. The change in visual acuity (VA), central retinal thickness (CRT) and any incidences of adverse effects were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>19 eyes of 13 patients received a mean of 3.3 injections at a mean interval of 11.1 weeks. The median VA improved from 0.40 logMAR (20\/50) to 0.35 logMAR (20\/44) after a mean period of 13 weeks after the last injection, which was statistically significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). The CRT reduced from 517 microns to 237 microns (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). One patient had an episode of intraocular inflammation, which was treated successfully with topical steroids. The same patient again received brolucizumab with no recurrent inflammation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Intravitreal brolucizumab helped improve visual acuity in patients with P-DME and achieved a reduction of 54.1% in the CRT at a longer mean reinjection interval. The rate of intraocular inflammation was 5.2% without any permanent visual impairment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00708-y","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:31:46Z","timestamp":1759235506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cReal world outcomes of intravitreal brolucizumab for persistent diabetic macular edema\u201d"],"prefix":"10.1186","volume":"11","author":[{"given":"Saarang","family":"Hansraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal Ramesh","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudit","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"4","key":"708_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11892-012-0283-6","volume":"12","author":"J Ding","year":"2012","unstructured":"Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346\u201354.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"708_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ajo.2013.11.012","volume":"157","author":"P Mitchell","year":"2014","unstructured":"Mitchell P, Wong TY, Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol. 2014;157(3):505\u201313.e1-8.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"708_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","volume":"68","author":"OA Sorour","year":"2023","unstructured":"Sorour OA, Levine ES, Baumal CR, Elnahry AG, Braun P, Girgis J, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023;68(2):147\u201374.","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"708_CR4","doi-asserted-by":"publisher","first-page":"e0222364","DOI":"10.1371\/journal.pone.0222364","volume":"14","author":"MY Choi","year":"2019","unstructured":"Choi MY, Jee D, Kwon JW. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS ONE. 2019;14(9):e0222364.","journal-title":"PLoS ONE"},{"issue":"6","key":"708_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00417-017-3624-y","volume":"255","author":"B Bahrami","year":"2017","unstructured":"Bahrami B, Hong T, Zhu M, Schlub TE, Chang A. Switching therapy from bevacizumab to Aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1133\u201340.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"708_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Diabetic retinopathy clinical research network. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or Ranibizumab for Central-Involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257\u201369.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"708_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"387","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, et al. DRCR retina network. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med. 2022;387(8):692\u2013703.","journal-title":"N Engl J Med"},{"issue":"2","key":"708_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41433-021-01722-8","volume":"36","author":"M Iglicki","year":"2022","unstructured":"Iglicki M, Gonz\u00e1lez DP, Loewenstein A, Zur D. Next-generation anti-VEGF agents for diabetic macular oedema. Eye (Lond). 2022;36(2):273\u20137.","journal-title":"Eye (Lond)"},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, et al. KESTREL and KITE: 52-Week results from two phase III pivotal trials of Brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"708_CR10","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1177\/11206721211059332","volume":"32","author":"HV Nguyen","year":"2022","unstructured":"Nguyen HV, Li AS, Silva AR, Leng T. Ocular adverse events following intravitreal Brolucizumab for neovascular age-related macular degeneration at a single tertiary care center. Eur J Ophthalmol. 2022;32(5):2747\u201351.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"708_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.18502\/jovr.v16i4.9757","volume":"16","author":"T Motevasseli","year":"2021","unstructured":"Motevasseli T, Mohammadi S, Abdi F, Freeman WR. Side effects of Brolucizumab. J Ophthalmic Vis Res. 2021;16(4):670\u20135.","journal-title":"J Ophthalmic Vis Res"},{"issue":"14","key":"708_CR12","first-page":"3025","volume":"53","author":"J Gaudreault","year":"2012","unstructured":"Gaudreault J, Gunde T, Floyd HS, et al. Preclinical Pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Investig Ophthalmol Vis Sci. 2012;53(14):3025.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"708_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","volume":"195","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, et al. Diabetic retinopathy clinical research network. Early response to Anti-Vascular endothelial growth factor and Two-Year outcomes among eyes with diabetic macular edema in protocol T. Am J Ophthalmol. 2018;195:93\u2013100.","journal-title":"Am J Ophthalmol"},{"key":"708_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and Long-Term responses to Anti-Vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"111","key":"708_CR15","doi-asserted-by":"publisher","first-page":"18353","DOI":"10.1038\/s41598-021-97644-2","volume":"15","author":"JS Kim","year":"2021","unstructured":"Kim JS, Lee S, Kim JY, Seo EJ, Chae JB, Kim DY. Visual\/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year. Sci Rep. 2021;15(111):18353.","journal-title":"Sci Rep"},{"key":"708_CR16","doi-asserted-by":"crossref","unstructured":"Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014; 34(4).","DOI":"10.1097\/IAE.0b013e3182a48958"},{"issue":"5","key":"708_CR17","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","volume":"67","author":"K Madjedi","year":"2022","unstructured":"Madjedi K, Pereira A, Ballios BG, Arjmand P, Kertes PJ, Brent M, et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: A systematic review. Surv Ophthalmol. 2022;67(5):1364\u201372.","journal-title":"Surv Ophthalmol"},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/OPTH.S286665","volume":"15","author":"DJ Ramsey","year":"2021","unstructured":"Ramsey DJ, Poulin SJ, LaMonica LC, Blaha GR, Barouch FC, Chang J, et al. Early conversion to Aflibercept for persistent diabetic macular edema results in better visual outcomes and lower treatment costs. Clin Ophthalmol. 2021;15:31\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"708_CR19","doi-asserted-by":"publisher","first-page":"10901","DOI":"10.1038\/s41598-023-37726-5","volume":"13","author":"T Hirano","year":"2023","unstructured":"Hirano T, Kumazaki A, Tomihara R, Ito S, Hoshiyama K, Murata T. Evaluating initial responses to Brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Sci Rep. 2023;13(1):10901.","journal-title":"Sci Rep"},{"issue":"12","key":"708_CR20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","volume":"141","author":"RP Singh","year":"2023","unstructured":"Singh RP, Barakat MR, Ip MS, Wykoff CC, Eichenbaum DA, Joshi S, Warrow D, et al. Efficacy and safety of Brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial. JAMA Ophthalmol. 2023;141(12):1152\u201360.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"708_CR21","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/IAE.0000000000003914","volume":"43","author":"S Vujosevic","year":"2023","unstructured":"Vujosevic S, Ting DSW. Is central retina thickness the most relevant parameter in the management of diabetic macular edema?? Retina. 2023;43(10):1639\u201343.","journal-title":"Retina"},{"issue":"7","key":"708_CR22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal Occlusion-Related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050\u20139.","journal-title":"Ophthalmology"},{"issue":"4","key":"708_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, et al. Occlusive retinal vasculitis following intravitreal Brolucizumab. J Vitreoretin Dis. 2020;4(4):269\u201379.","journal-title":"J Vitreoretin Dis"},{"issue":"10","key":"708_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology. 2020;127(10):1345\u201359.","journal-title":"Ophthalmology"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00708-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:05:32Z","timestamp":1759277132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00708-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00708-y","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was conducted after obtaining permission from the institute ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"LEC- BHR-P12-21-781.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB"}},{"value":"Written informed consent was obtained from each participant of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB"}}],"article-number":"101"}}